Biocept and Aegea Biotechnologies will be working together to develop a PCR-based COVID-19 assay using Switch-Blocker technology. The deal's financial terms were not disclosed.
An initial public offering of more than 8.8 million shares of common stock has been priced by Acutus Medical at $18 each with the goal of raising $158.8 million. The offering, set to close Aug. 10, includes a 30-day option for underwriters to buy 1,323,529 more shares.
Sight Diagnostics, an Israeli startup that developed a blood analysis machine that uses machine vision, raised $71 million in its Series D round. With the new capital in hand, the company will focus on sales in the US.
Digital breast tomography was more cost-effective than digital mammography in 66% of breast screening scenarios at a willingness-to-pay threshold of $38,500 per life-year gained and 36% of scenarios at a threshold of $22,000, according to a study in Radiology. The study found cost-effectiveness of DBT varied based on willingness-to-pay thresholds and digital mammography recall rates, researchers said.
Israel-based PregnanTech has created LIONESS, an implantable device that keeps the cervix elongated despite contractions and lessens the load on the cervix, helping prevent preterm birth.
The FDA has given expanded clearance to Adaptive Biotechnologies for its clonoSEQ assay that is used to evaluate minimal residual disease in chronic lymphocytic leukemia patients. The test can now be used to monitor and detect MRD in bone marrow or blood samples.
European regulators have given CE mark approval to DiaSorin for its Liaison Testosterone xt test that can help detect fertility disorders like hyperandrogenism and hypogonadism.
Join us this fall for a new conference experience -- The Virtual MedTech Conference! We have reimagined how to bring you valuable opportunities to learn, network and connect in today's world. Expect the same high-quality education, world-class speakers and valuable business development in a dynamic and immersive virtual format. In addition, you have the unique opportunity to experience more of the conference with on demand content and partnering from Sept. 8 to Oct. 23, and livestreamed sessions taking place from October 5-7. Registration is now open -- secure your pass today. Learn more.
With our member companies on the front lines of the fight against the COVID-19 pandemic, AdvaMed is working diligently to address the medtech industry's needs and provide resources that support you and your businesses during this challenging time. To better support you, we have launched a new COVID-19 Resource Center to provide important information to companies about the federal response to COVID-19, best practices and other valuable resources. Learn more.
